Log in

NYSE:GKOS - Glaukos Stock Price, Forecast & News

$59.25
+0.91 (+1.56 %)
(As of 12/11/2019 04:42 AM ET)
Today's Range
$57.76
Now: $59.25
$59.31
50-Day Range
$57.56
MA: $62.81
$66.06
52-Week Range
$50.60
Now: $59.25
$84.65
Volume434,127 shs
Average Volume430,411 shs
Market Capitalization$2.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone949-367-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$181.28 million
Book Value$4.98 per share

Profitability

Net Income$-12,950,000.00

Miscellaneous

Employees437
Market Cap$2.16 billion
Next Earnings Date2/26/2020 (Estimated)
OptionableOptionable

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.


Glaukos (NYSE:GKOS) Frequently Asked Questions

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos' earnings last quarter?

Glaukos Corp (NYSE:GKOS) released its quarterly earnings data on Wednesday, November, 6th. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.07. The medical instruments supplier had revenue of $58.51 million for the quarter, compared to analysts' expectations of $56.96 million. Glaukos had a negative net margin of 8.60% and a negative return on equity of 4.01%. The business's revenue was up 33.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) EPS. View Glaukos' Earnings History.

When is Glaukos' next earnings date?

Glaukos is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Glaukos.

What price target have analysts set for GKOS?

8 brokers have issued 12 month price targets for Glaukos' shares. Their forecasts range from $66.02 to $90.00. On average, they expect Glaukos' stock price to reach $74.57 in the next year. This suggests a possible upside of 25.9% from the stock's current price. View Analyst Price Targets for Glaukos.

What is the consensus analysts' recommendation for Glaukos?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Glaukos.

What are Wall Street analysts saying about Glaukos stock?

Here are some recent quotes from research analysts about Glaukos stock:
  • 1. According to Zacks Investment Research, "Glaukos is currently progressing with the U.S. commercial rollout of its next-generation iStent inject Trabecular Micro-Bypass device. It also initiated patient enrolment of key U.S. pivotal clinical studies for iDose Travoprost and iStent Infinite. Through continued investment and a new pharmaceutical development agreement with D. Western Therapeutic Institute Glaukos expanded its pharmaceutical capabilities. A strong pipeline is indicative of brighter prospects ahead. Management is optimistic about the recent Avedro buyout. The company outperformed the industry year-to-date. With respect to quarterly results, Glaukos exited the second quarter on a tepid note. Also, Glaukos faces cutthroat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning." (9/12/2019)
  • 2. BTIG Research analysts commented, "We maintain our Neutral rating on GKOS shares following a solid 1Q19 beat. Largely expected, GKOS delivered rev. of $54.0M vs. BTIG/Street est. of $49.7M/$50.2M as iStent inject conversions and OUS strength drove upside while competitive trialing was modest (below mgmt.’s initial expectations). CyPass share gains continue to buoy US results (we est. $9M-$10M/qtr.) Current business execution, market dynamics, and pricing all appear to be in-line to slightly better than originally guided with no material change to pipeline timelines. Against a ~$4M beat, mgmt. moved the lower-end of guidance up $5M (+$2.5M at the midpoint), sticking with a conservative (but optimistic) tone through the balance of the year. Mgmt. remains cautious around an increase in competitive trialing within the US combined with continued OUS challenges in the UK stemming from reimbursement cuts." (5/10/2019)

Has Glaukos been receiving favorable news coverage?

News stories about GKOS stock have been trending neutral recently, according to InfoTrie Sentiment. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Glaukos earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Glaukos.

Are investors shorting Glaukos?

Glaukos saw a increase in short interest in the month of October. As of October 31st, there was short interest totalling 7,250,000 shares, an increase of 12.1% from the September 30th total of 6,470,000 shares. Based on an average trading volume of 494,800 shares, the short-interest ratio is currently 14.7 days. Approximately 20.4% of the shares of the stock are short sold. View Glaukos' Current Options Chain.

Who are some of Glaukos' key competitors?

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include PTC Therapeutics (PTCT), Alibaba Group (BABA), Paypal (PYPL), Twilio (TWLO), NVIDIA (NVDA), Caterpillar (CAT), Baidu (BIDU), Splunk (SPLK), Boeing (BA) and Coupa Software (COUP).

Who are Glaukos' key executives?

Glaukos' management team includes the folowing people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 58)
  • Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)
  • Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)
  • Mr. Richard L. Harrison, Advisor (Age 62)
  • Dr. Mory Gharib Ph.D., Co-Founder

When did Glaukos IPO?

(GKOS) raised $76 million in an IPO on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Glaukos' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (3.95%), State Street Corp (2.36%), Peregrine Capital Management LLC (0.96%), Rhenman & Partners Asset Management AB (0.63%), C WorldWide Group Holding A S (0.46%) and Man Group plc (0.32%). Company insiders that own Glaukos stock include Chris M Calcaterra, Gilbert H Kliman, Jonathan Silverstein, Joseph E Gilliam, Orbimed Advisors Llc, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos.

Which major investors are selling Glaukos stock?

GKOS stock was sold by a variety of institutional investors in the last quarter, including C WorldWide Group Holding A S, Millennium Management LLC, Strs Ohio, Rhenman & Partners Asset Management AB, SG Americas Securities LLC, First Trust Advisors LP, Gilder Gagnon Howe & Co. LLC and Taylor Frigon Capital Management LLC. Company insiders that have sold Glaukos company stock in the last year include Chris M Calcaterra and Joseph E Gilliam. View Insider Buying and Selling for Glaukos.

Which major investors are buying Glaukos stock?

GKOS stock was acquired by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Man Group plc, California Public Employees Retirement System, State of New Jersey Common Pension Fund D, Russell Investments Group Ltd., State Street Corp, Barclays PLC and Envestnet Asset Management Inc.. View Insider Buying and Selling for Glaukos.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $59.25.

How big of a company is Glaukos?

Glaukos has a market capitalization of $2.16 billion and generates $181.28 million in revenue each year. The medical instruments supplier earns $-12,950,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Glaukos employs 437 workers across the globe.View Additional Information About Glaukos.

What is Glaukos' official website?

The official website for Glaukos is http://www.glaukos.com/.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]


MarketBeat Community Rating for Glaukos (NYSE GKOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  353 (Vote Outperform)
Underperform Votes:  265 (Vote Underperform)
Total Votes:  618
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2019 by MarketBeat.com Staff

Featured Article: Back-End Load

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel